Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 22

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
 lease through October 2029.The weighted average remaining lease term and weighted average discount rate for the operating leases as of June 30, 2025 and December 31, 2024 were as follows:June 30, 2025December 31, 2024Weighted average remaining lease term (in months)2529Weighted average discount rate4.7 %4.7 %The future minimum annual lease payments under these operating leases as of June 30, 2025 are as follows:

18

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025(Unaudited)

(in thousands)Year ending December 31,AmountRemainder of fiscal 2025$81120261,285202714720281472029100Thereafter—Total lease payments2,490Less imputed interest(104)Total lease liability2,386Less current portion of lease liability(1,550)Long-term portion of operating lease liability$836Operating cash outflows for amounts included in the measurement of lease liabilities were $761 thousand and $725 thousand for the six months ended June 30, 2025 and 2024, respectively.The Company recorded the following lease and variable lease expenses for the three and six months ended June 30, 2025 and 2024: (in thousands)Three Months Ended June 30, 2025Three Months Ended June 30, 2024Six Months Ended June 30, 2025Six Months Ended June 30, 2024 Operating lease expense$366 $354 $730 $702 Variable lease expense12 — 23 — Total lease expense$378 $354 $753 $702 

Note 11 — Employee Benefit Plans 

The Company operates a defined benefit pension plan in Switzerland (the “Plan”) and a defined contribution pension plan in the United Kingdom, in accordance with local regulations and practices. As of June 30, 2025, the Plan covers the Company’s employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment. 

19

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025(Unaudited)

Components of Net Periodic Benefit Cost under the Plan(in thousands)Three Months Ended June 30, 202